Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
LYRA Lyra Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: LYRA
Price (delayed)
$0.0982
Market cap
$6.51M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.21
Enterprise value
$6.14M
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose
Highlights
The EPS is up by 15% since the previous quarter
The debt has declined by 12% year-on-year and by 3% since the previous quarter
Lyra Therapeutics's net income has decreased by 15% YoY but it has increased by 15% QoQ
LYRA's equity has dropped by 95% year-on-year and by 67% since the previous quarter
LYRA's quick ratio is down by 38% YoY and by 13% from the previous quarter
Key stats
What are the main financial stats of LYRA
Market
Valuations
Earnings
Shares outstanding
66.27M
Market cap
$6.51M
Enterprise value
$6.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.67
Price to sales (P/S)
5.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.18
Revenue
$1.19M
Gross profit
$1.19M
Operating income
-$81.67M
Net income
-$79.53M
EBIT
-$79.5M
EBITDA
-$79.04M
Free cash flow
-$56.59M
Per share
Balance sheet
Liquidity
EPS
-$1.21
EPS diluted
-$1.21
Free cash flow per share
-$0.86
Book value per share
$0.06
Revenue per share
$0.02
TBVPS
$0.86
Total assets
$56.32M
Total liabilities
$52.44M
Debt
$33.36M
Equity
$3.87M
Working capital
$22.44M
Debt to equity
8.61
Current ratio
2.96
Quick ratio
2.94
Net debt/EBITDA
0
Margins
Efficiency
Dividend
EBITDA margin
-6,669.9%
Gross margin
100%
Net margin
-6,711.4%
Operating margin
-6,891.6%
Return on assets
-107.5%
Return on equity
-474.4%
Return on invested capital
-131.7%
Return on capital employed
-177.3%
Return on sales
-6,708.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LYRA stock price
How has the Lyra Therapeutics stock price performed over time
Intraday
4.03%
1 week
-9.33%
1 month
4.25%
1 year
-74.59%
YTD
-52.42%
QTD
-22.25%
Financial performance
How have Lyra Therapeutics's revenue and profit performed over time
Revenue
$1.19M
Gross profit
$1.19M
Operating income
-$81.67M
Net income
-$79.53M
Gross margin
100%
Net margin
-6,711.4%
The net margin has dropped by 64% year-on-year and by 10% since the previous quarter
Lyra Therapeutics's operating margin has shrunk by 58% YoY and by 10% QoQ
The company's revenue fell by 29% YoY and by 23% QoQ
Lyra Therapeutics's gross profit has decreased by 29% YoY and by 23% from the previous quarter
Price vs fundamentals
How does LYRA's price correlate with its fundamentals
Growth
What is Lyra Therapeutics's growth rate over time
Valuation
What is Lyra Therapeutics stock price valuation
P/E
N/A
P/B
1.67
P/S
5.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.18
The EPS is up by 15% since the previous quarter
LYRA's equity has dropped by 95% year-on-year and by 67% since the previous quarter
LYRA's price to book (P/B) is 39% more than its last 4 quarters average of 1.2 but 12% less than its 5-year quarterly average of 1.9
The price to sales (P/S) is 41% lower than the last 4 quarters average of 9.3
The company's revenue fell by 29% YoY and by 23% QoQ
Efficiency
How efficient is Lyra Therapeutics business performance
The return on assets has dropped by 107% year-on-year and by 10% since the previous quarter
LYRA's return on invested capital has dropped by 95% year-on-year and by 20% since the previous quarter
The return on equity has dropped by 79% since the previous quarter
The ROS has dropped by 64% year-on-year and by 10% since the previous quarter
Dividends
What is LYRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LYRA.
Financial health
How did Lyra Therapeutics financials performed over time
The total assets is 7% greater than the total liabilities
The total assets has dropped by 60% year-on-year and by 15% since the previous quarter
The current ratio has contracted by 38% YoY and by 13% from the previous quarter
The company's debt to equity has surged by 190% QoQ
LYRA's equity has dropped by 95% year-on-year and by 67% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.